

1. Status Of The Claims

Applicant acknowledges renumbering of the claims as claims 1-130.

2. Priority Claim

While the Examiner has acknowledged Applicant's claim for priority to Austrian Application A89599, he has indicated that no certified copy of the Austrian application has been submitted.

Applicant respectfully notes that, in the papers originally filed November 16, 2001, a certified copy of said document was in fact submitted. Attached hereto is a copy of the paper, "Submission of Priority Document," as well as the stamped return receipt postcard indicating that the priority document was received by the Patent Office. Therefore, Applicant believes that the requirements for the priority claim have been met. However, if the Examiner is unable to locate the Austrian priority document, another will be obtained by Applicant upon the Examiner's request.

3. Response To Restriction Requirement


The Examiner has identified twelve separate inventions in the pending claims, and has required Applicant to restrict prosecution in this application to one of those inventions. In response, Applicant hereby elects to prosecute the invention of Group I, Claims 1-104, drawn to a topical medicament to stop bleeding, without prejudice to the prosecution of the subject matter of other claims in other patent applications. Applicant makes this election without traverse.

In addition, for the invention of Group I, the Examiner requires Applicant to select one of the following species: a structural protein (claims 2-5), a cell stimulating factor

(claims 5-8), an enzyme or enzyme inhibitor (claims 9-16), an antiadherent, antioxidant or antimicrobial (claims 17-32), a blood coagulation zymogen (claims 33-64) or a particulate cell element (claims 65-95). Applicant respectfully traverses this requirement. Claim 1 requires the presence of components (i)-(iv). The dependent claims do not relate to *species* of components (i)-(iv); rather, they add additional components (the language "further comprising" is used). Accordingly, Applicant should not be required to limit examination of the claims to any of the suggested categories of subject matter, as they do not, in fact, represent species of claim 1 but rather the invention of claim 1 containing additional components. Applicant does not admit, in traversing the species requirement, that the addition of any of these additional components, beyond the four recited in claim 1, is an obvious variant.

Despite traversing the species requirement, Applicant, because he is required to select one of the offered species, selects species (1), structural proteins, as covered in claims 2-4, 6, 7, 8, 10, 11, 12, 14, 15, 16, 18, 19, 20, 22, 23, 24, 26, 27, 28, 30, 31, 32, 34, 35, 36, 38, 39, 40, 42, 43, 44, 46, 47, 48, 50, 51, 52, 54, 55, 56, 58, 59, 60, 62, 63, 64, 66, 68, 70, 72, 74, 76, 78, 80, 81, 83, 85, 87, 89, 91, 93, 95, 97 and 98. This election is made without prejudice to any of the other categories of subject matter offered as species (2)-(6).

Respectfully submitted,
BAKER BOTTS LLP



Lisa B. Kole
Patent Office Reg. No. 35,225
Attorneys for Applicant
(212) 408-2500